Ticker
BMY

Price
65.16
Stock movement down
-0.32 (-0.49%)
Company name
Bristol-Myers Squibb Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
136.76B
Ent value
193.34B
Price/Sales
2.96
Price/Book
4.39
Div yield
3.50%
Div growth
6.72%
Growth years
12
FCF payout
38.78%
Trailing P/E
21.61
Forward P/E
7.95
PEG
1.17
EPS growth
10.90%
1 year return
-13.41%
3 year return
2.28%
5 year return
4.84%
10 year return
3.19%
Last updated: 2023-06-07
Bristol-Myers Squibb Company (NYSE:NYSE:BMY) 2023 Virtual ASCO Investor Event Conference June 6, 2023 8:00 AM ETCompany ParticipantsTim Power - Investor RelationsSamit Hirawat - Chief...
June 6, 2023

iO Charts is a Seeking Alpha partner

Bristol-Myers Squibb has seen its share price trend down as investors remain concerned about loss of exclusivity. Click for more on BMY stock prospects.
June 5, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.28
Dividend yield3.50%
Payout frequencyQuarterly
Maximum yield4.03%
Average yield3.13%
Minimum yield2.55%
Discount to avg yield10.43%
Upside potential11.64%
Yield as % of max yield86.88%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.50%
Current yield distribution11.90%
Yield at 100% (Min)2.55%
Yield at 90%2.81%
Yield at 80%2.89%
Yield at 50% (Median)3.12%
Yield at 20%3.38%
Yield at 10%3.53%
Yield at 0% (Max)4.03%

Dividend per share

Loading...
Dividend per share data
Years of growth12 years
CCC statusDividend Contender
Dividend per share2.28
Payout frequencyQuarterly
Ex-div date6 Apr 2023
EPS (TTM)2.98
EPS (1y forward)8.20
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BMYS&P500
DGR MR5.56%-15.45%
DGR TTM7.77%11.27%
DGR 3 years9.62%4.00%
DGR 5 years6.72%5.65%
DGR 10 years4.73%7.37%
DGR 15 years4.48%5.83%
Time since last change announced182 days
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM73.24%38.78%
Average--
Forward27.80%-
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E21.61
Price to OCF10.47
Price to FCF11.45
Price to EBITDA7.36
EV to EBITDA10.41

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.96
Price to Book4.39
EV to Sales4.19
Bristol Myers Squibb has been overlooked by investors as of late. Find out what makes BMY stock an attractive long-term investment.
June 5, 2023

iO Charts is a Seeking Alpha partner

The author identifies Bristol-Myers Squibb (BMY) as a potentially attractive investment for long-term dividend growth investors. Click to read my analysis.
May 30, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count2.10B
EPS (TTM)2.98
FCF per share (TTM)5.63

Income statement

Loading...
Income statement data
Revenue (TTM)46.16B
Gross profit (TTM)36.02B
Operating income (TTM)9.21B
Net income (TTM)6.33B
EPS (TTM)2.98
EPS (1y forward)8.20

Margins

Loading...
Margins data
Gross margin (TTM)78.04%
Operating margin (TTM)19.96%
Profit margin (TTM)13.71%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash9.12B
Net receivables9.89B
Total current assets27.27B
Goodwill21.15B
Intangible assets35.86B
Property, plant and equipment0.00
Total assets96.82B
Accounts payable3.04B
Short/Current long term debt39.32B
Total current liabilities21.89B
Total liabilities65.70B
Shareholder's equity31.12B
Net tangible assets-25.95B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)13.07B
Capital expenditures (TTM)1.12B
Free cash flow (TTM)11.95B
Dividends paid (TTM)4.63B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity20.33%
Return on Assets6.53%
Return on Invested Capital8.98%
Cash Return on Invested Capital16.96%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open65.16
Daily high65.33
Daily low64.75
Daily Volume4.92M
All-time high81.13
1y analyst estimate81.09
Beta0.45
EPS (TTM)2.98
Dividend per share2.28
Ex-div date6 Apr 2023
Next earnings date27 Jul 2023

Downside potential

Loading...
Downside potential data
BMYS&P500
Current price drop from All-time high-19.68%-10.71%
Highest price drop-76.73%-56.47%
Date of highest drop16 Oct 20089 Mar 2009
Avg drop from high-34.04%-11.53%
Avg time to new high41 days13 days
Max time to new high4176 days1805 days
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 30, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 26, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BMY (Bristol-Myers Squibb Company) company logo
Marketcap
136.76B
Marketcap category
Large-cap
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Employees
34300
SEC filings
CEO
Giovanni Caforio
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 25, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 22, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 21, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 17, 2023
Bristol-Myers Squibb Company (NYSE:NYSE:BMY) Bank of America Securities 2023 Health Care Conference May 9, 2023 11:40 AM ETCompany ParticipantsAdam Lenkowsky - EVP, Head of...
May 13, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 11, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 9, 2023
Bristol-Myers Squibb stock delivered a poor performance in 2023 despite solid FY 2022 and Q1 2023 results. Find out why BMY is a Buy.
May 5, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
May 1, 2023
Bristol-Myers Squibb announced Q123 revenue declined year-on-year, although EPS grew, and guidance for 2023 was upheld. Click for my BMY Q1 earnings review.
April 28, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
April 28, 2023
Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.
April 28, 2023
iO Charts is a Seeking Alpha partnerNext page